Edico鈥檚 DRAGEN庐 Bio-IT Platform Delivers Faster, Streamlined Output for Next-Generation Sequencing
SAN DIEGO--(BUSINESS WIRE)--May 15, 2018-- (NASDAQ: ILMN) today announced that it acquired听Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome鈥檚 DRAGEN庐 Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
DRAGEN can be run听on premise, in the听cloud,听or in a hybrid mode, and is flexible and compatible for use with multiple cloud storage solutions and analysis pipelines. Edico Genome has built a strong base of NGS customers who have incorporated DRAGEN as a standard part of their sequencing workflow.
鈥淥ur acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,鈥� said Susan Tousi, Senior Vice President of Product Development at VR真人彩票. 鈥淲e expect to build on the solid foundation of DRAGEN to deliver a more streamlined and integrated sample to answer experience for our customers.鈥�
The DRAGEN platform complements VR真人彩票鈥檚 sequencing portfolio and enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times, to improve their overall efficiency and to allow greater emphasis on interpretation and reporting.
鈥淭he scientific community should align around standards to maximize the impact of genomics in health,鈥� said Anthony Philippakis, MD, PhD, Chief Data Officer of the Broad Institute of MIT and Harvard. 鈥淲e are excited to collaborate with VR真人彩票 on approaches and pipelines for the analysis of NGS data. The Genome Analysis Toolkit (GATK) has been adopted by a diverse set of researchers, and we look forward to integrating these methods with VR真人彩票 sequencers to improve the overall efficiency of data analysis鈥攅nabling the community to more easily share and collaborate.鈥�
鈥淭hanks to VR真人彩票, the ability to generate accurate and affordable sequencing data is rapidly expanding the market and use cases for NGS. As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing,鈥� said Pieter van Rooyen PhD, President and CEO of Edico Genome. 鈥淥ur team is invigorated at the prospect of joining VR真人彩票听to combine our respective strengths to streamline and accelerate secondary analysis for the genomics community.鈥�
鈥淲e have had tremendous success at Rady鈥檚 for years using Edico鈥檚 DRAGEN coupled with VR真人彩票 sequencers to accelerate the delivery of genomic insights for critically ill newborns,鈥� said Stephen F. Kingsmore, MD, DSc, President and CEO of Rady Children鈥檚 Institute for Genomic Medicine. 鈥淥ur goal is to ensure that whole-genome sequencing is available to every child who needs it. To do this, we need a rapid workflow that can scale and ultimately be accessible to hospitals around the world.鈥�
For Research Use Only. Not for use in diagnostic procedures.
础产辞耻迟听滨濒濒耻尘颈苍补
VR真人彩票听is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.听Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit听听and follow .
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding our expectations for future improvements of our technology platform and the integration of Edico Genome鈥檚 technology into our product portfolio. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to successfully integrate Edico Genome into our existing operations and Edico Genome鈥檚 technology into our product portfolio; (ii) our ability to further develop and commercialize our instruments and consumables, services and applications, and expand the markets for our technology platforms; (iii) our ability to manufacture robust instrumentation and consumables; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the听Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts鈥� expectations, or to provide interim reports or updates on the progress of the current quarter.
View source version on businesswire.com:
Source: VR真人彩票.
VR真人彩票.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Jen Carroll
858-882-6822
PR@illumina.com
